Research programme: fibrosis and organ failure therapeutics - Biogen

Drug Profile

Research programme: fibrosis and organ failure therapeutics - Biogen

Latest Information Update: 20 Mar 2017

Price : $50

At a glance

  • Originator University of California at San Francisco
  • Developer Stromedix
  • Class Monoclonal antibodies
  • Mechanism of Action Integrin alphaVbeta5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Fibrosis; Multiple organ failure

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Fibrosis in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-organ-failure in USA
  • 19 Nov 2010 Preclinical trials in Fibrosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top